Previous Page
32
nanotimes
Companies Facts
round was led by Wellcome Trust, a London- based charity that funds health research with a $23 billion investment portfolio, San Francisco-based Siluria said yesterday in a statement. Existing investors Alloy Ventures, Arch Venture Partners, Kleiner Perkins Caufield & Byers, Altitude Life Science Ventures, Lux Capital and Presidio Ventures also participated in the funding.
p3 Diamond Technologies, Inc. (sp3), a leading supplier of diamond products, equipment and
services, has selected Techmart Industrial Limi- ted (Techmart) as its distributor responsible for the People’s Republic of China, Hong Kong Special Ad- ministrative Region and Taiwan. The relationship will allow Techmart to actively market, sell and service sp3’s hot filament CVD diamond deposition reactors, including the single-chamber Model 655 and the dual-chamber Model 665.
“We see tremendous opportunity in China, Hong Kong and Taiwan for a variety of CVD diamond ap- plications, including diamond-coated cutting tools for machining non-ferrous materials, wear applications, electrodes and wafer-scale diamond for semiconduc- tor related applications,” said Gary Schoettmer, vice president of operations for sp3 Diamond Technolo- gies, Inc.
The Model 655 Series Hot Filament CVD Reactor offers an industry-leading solution for manufacturing nano- or micro-crystalline diamond films.
http://www.sp3diamondtech.com S
pire Corporation (NASDAQ: SPIR), a global solar company providing capital equipment and turn-
key manufacturing lines to produce photovoltaic (PV) modules and engineering, procurement and construction (EPC) integration services for solar sy- stems, reported revenues from continuing operations for the third quarter ended September 30, 2011 of $8.9 million. This represents a 57% reduction from $20.6 million for the same quarter of 2010. Net loss for the third quarter of 2011 was $1.8 million, or $(0.21) per share, compared to a net loss of $915 thousand, or $(0.11) per share for the third quarter of 2010.
Net cash used in operating activities of continuing operations was $3.4 million for the nine months ended September 30, 2011, as compared to $2.4 million for the same period in 2010. As of September 30, 2011, the Company had unrestricted cash and cash equivalents of $2.3 million.
tarpharma (ASX:SPL; OCTQX:SPHRY) released its Appendix 4C - Quarterly Cashflow report for the
period ended September 30, 2011. The cash balance at end of September 2011 was $17m. Total opera- ting and investing cash outflow for the quarter was $2.1m.
Major activities during the quarter included:
• Positive End of Phase 2 meeting with the FDA, paving the way for commencement of the Phase 3 program for VivaGel® Bacterial Vaginosis (BV);
for the treatment of
11-10 :: October 2011